To the full analysis
Buyback calculator for Inhibrx Biosciences
Inhibrx Biosciences stock: key metrics
INBXInhibrx Biosciences had an operating margin of −10,386.5% and a return on invested capital (ROIC) of −83.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | −154.9% | −182.2% | −124.0% |
| 2017 | −204.0% | −235.1% | −231.7% |
| 2018 | −289.2% | −343.4% | −362.6% |
| 2019 | −426.9% | −450.4% | −565.3% |
| 2020 | 0.0% | −526.6% | −594.3% |
| 2021 | 62.3% | −1,076.1% | −1,147.6% |
| 2022 | −4,926.7% | −5,890.4% | −6,625.3% |
| 2023 | 33.8% | −12,178.9% | −13,408.9% |
| 2024 | −1,042.5% | −165,724.0% | 843,786.0% |
| 2025 | −91.0% | −10,386.5% | −10,773.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | 89.4% | −47.4% | −38.9% |
| 2017 | 67.6% | −92.4% | −100.0% |
| 2018 | 54.1% | no data | −100.0% |
| 2019 | 54.9% | no data | −100.0% |
| 2020 | −100.0% | −85.6% | −53.0% |
| 2021 | −100.0% | −49.7% | −54.3% |
| 2022 | −100.0% | −51.7% | −49.9% |
| 2023 | −100.0% | −67.0% | −78.4% |
| 2024 | 200.0% | no data | 200.0% |
| 2025 | −100.0% | −83.1% | −95.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.